Maspero J, Adir Y, Al-Ahmad M, Celis-Preciado CA, Colodenco FD, Giavina-Bianchi P, et al. Type 2 inflammation in asthma and other airway diseases. ERJ Open Res. 2022;8(3):00576–2021. https://doi.org/10.1183/23120541.00576-2021.

Article  PubMed  PubMed Central  Google Scholar 

Ogulur I, Mitamura Y, Yazici D, Pat Y, Ardicli S, Li M, et al. Type 2 immunity in allergic diseases. Cell Mol Immunol. 2025;22(3):211–42. https://doi.org/10.1038/s41423-025-01261-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Y, Yang T, Zhang J, Chen X, Chen X, Cheng Z, et al. Type 2 inflammation in chronic obstructive pulmonary disease: A promising treatable trait and practice recommendations. Chin Med J Pulm Crit Care Med. 2025;3(4):225–45. https://doi.org/10.1016/j.pccm.2025.11.004.

Article  PubMed  PubMed Central  Google Scholar 

Carriera L, Fantò M, Martini A, D’Abramo A, Puzio G, Scaramozzino MU, et al. Combination of biological therapy in severe asthma: Where we are? J Pers Med. 2023;13(11):1594. https://doi.org/10.3390/jpm13111594.

Article  PubMed  PubMed Central  Google Scholar 

Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Cole J, Bafadhel M, et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2023;389(3):205–14. https://doi.org/10.1056/NEJMoa2303951.

Article  CAS  PubMed  Google Scholar 

Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, et al. Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation. N Engl J Med. 2024;390(24):2274–83. https://doi.org/10.1056/NEJMoa2401304.

Article  CAS  PubMed  Google Scholar 

Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, et al. Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2025;13(3):234–43. https://doi.org/10.1016/S2213-2600(24)00409-0.

Article  CAS  PubMed  Google Scholar 

Fujimura KE, Lynch SV. Microbiota in allergy and asthma and the emerging relationship with the gut microbiome. Cell Host Microbe. 2015;17(5):592–602. https://doi.org/10.1016/j.chom.2015.04.007.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang YJ, Marsland BJ, Bunyavanich S, O’Mahony L, Leung DYM, Muraro A, et al. The microbiome in allergic disease: current understanding and future opportunities-2017 PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology. J Allergy Clin Immunol. 2017;139(4):1099–110. https://doi.org/10.1016/j.jaci.2017.02.007.

Article  PubMed  PubMed Central  Google Scholar 

Hoggard M, Wagner Mackenzie B, Jain R, Taylor MW, Biswas K, Douglas RG. Chronic rhinosinusitis and the evolving understanding of microbial ecology in chronic inflammatory mucosal disease. Clin Microbiol Rev. 2017;30(1):321–48. https://doi.org/10.1128/CMR.00060-16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, et al. Disordered microbial communities in asthmatic airways. PLoS ONE. 2010;5(1):e8578. https://doi.org/10.1371/journal.pone.0008578.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Durack J, Lynch SV, Nariya S, Bhakta NR, Beigelman A, Castro M, et al. Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment. J Allergy Clin Immunol. 2017;140(1):63–75. https://doi.org/10.1016/j.jaci.2016.08.055.

Article  CAS  PubMed  Google Scholar 

Verma A, Bhagchandani T, Rai A, Nikita, Sardarni UK, Bhavesh NS, et al. Short-Chain Fatty Acid (SCFA) as a Connecting Link between Microbiota and Gut-Lung Axis—A Potential Therapeutic Intervention to Improve Lung Health. ACS Omega. 2024;9(13):14648–71. https://doi.org/10.1021/acsomega.3c05846.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Budden KF, Gellatly SL, Wood DLA, Cooper MA, Morrison M, Hugenholtz P, et al. Emerging pathogenic links between microbiota and the gut-lung axis. Nat Rev Microbiol. 2017;15(1):55–63. https://doi.org/10.1038/nrmicro.2016.142.

Article  CAS  PubMed  Google Scholar 

Dang AT, Marsland BJ. Microbes, metabolites, and the gut-lung axis. Mucosal Immunol. 2019;12(4):843–50. https://doi.org/10.1038/s41385-019-0160-6.

Article  CAS  PubMed  Google Scholar 

Cait A, Hughes MR, Antignano F, Cait J, Dimitriu PA, Maas KR, et al. Microbiome-driven allergic lung inflammation is ameliorated by short-chain fatty acids. Mucosal Immunol. 2018;11(3):785–95. https://doi.org/10.1038/mi.2017.75.

Article  CAS  PubMed  Google Scholar 

Kilic E, Basaran P. Dietary fatty acids modulate gut microbiota-derived Trimethylamine-N-Oxide: potential mechanisms and future perspective. Nutrients. 2025;17(23):3787. https://doi.org/10.3390/nu17233787.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bernardi F, D’Amico F, Bencardino S, Faggiani I, Fanizza J, Zilli A, et al. Gut microbiota metabolites: unveiling their role in inflammatory bowell diseases and fibrosis. Pharmaceuticals Basel. 2024;17(3):347. https://doi.org/10.3390/ph17030347.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cicchinelli S, Gemma S, Pignataro G, Piccioni A, Ojetti V, Gasbarrini A, et al. Intestinal fibrogenesis in inflammatory bowell diseases: exploring the potential role of gut microbiota metabolites as modulators. Pharmaceuticals (Basel). 2024;17(4):490. https://doi.org/10.3390/ph17040490.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cicchinelli S, Rosa F, Manca F, Zanza C, Ojetti V, Covino M, et al. The impact of smoking on microbiota: a narrative review. Biomedicines. 2023;11(4):1144. https://doi.org/10.3390/biomedicines11041144.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saviano A, Petruzziello C, Brigida M, Morabito Loprete MR, Savioli G, Migneco A, et al. Gut microbiota alteration and its modulation with probiotics in Celiac Disease. Biomedicines. 2023;11(10):2638. https://doi.org/10.3390/biomedicines11102638.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gabrielli M, Zileri Dal Verme L, Zocco MA, Nista EC, Ojetti V, Gasbarrini A. The role of the gastrointestinal microbiota in Parkinson’s Disease. Biomolecules. 2024;15(1):26. https://doi.org/10.3390/biom15010026.

Article  CAS  PubMed  PubMed Central  Google Scholar 

D’Avino P, Kim J, Li M, Gessner P, Westermann P, Pat Y, et al. Distinct roles of IL-4, IL‐13, and IL‐22 in human skin barrier dysfunction and atopic dermatitis. Allergy. 2026;81(2):480–97. https://doi.org/10.1111/all.70060.

Article  CAS  PubMed  Google Scholar 

McLeod JJA, Baker BN, Ryan JJ. Mast cell production and response to IL-4 and IL-13. Cytokine. 2015;75(1):57–61. https://doi.org/10.1016/j.cyto.2015.05.019.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wynn TA. IL-13 effector functions. Annu Rev Immunol. 2003;21:425–56. https://doi.org/10.1146/annurev.immunol.21.120601.141142.

Article  CAS  PubMed  Google Scholar 

Didriksen BJ, Eshleman EM, Alenghat T. Epithelial regulation of microbiota-immune cell dynamics. Mucosal Immunol. 2024;17(2):303–13. https://doi.org/10.1016/j.mucimm.2024.02.008.

Article